ALT Altimmune Inc

USD 8.01 0.00 0
Icon

Altimmune Inc (ALT) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 8.01

0.00 (0.00)%

USD 0.57B

4.04M

USD 17.89(+123.33%)

USD 24.48 (+205.62%)

Icon

ALT

Altimmune Inc (USD)
COMMON STOCK | NSD
USD 8.01
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Buy

Average User
Rating

USD 0.57B

USD 24.48 (+205.62%)

USD 8.01

Altimmune Inc (ALT) Stock Forecast

Show ratings and price targets of :
USD 17.89
(+123.33%)

Based on the Altimmune Inc stock forecast from 5 analysts, the average analyst target price for Altimmune Inc is USD 17.89 over the next 12 months. Altimmune Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Altimmune Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Altimmune Inc’s stock price was USD 8.01. Altimmune Inc’s stock price has changed by +10.94% over the past week, +16.26% over the past month and +80.00% over the last year.

No recent analyst target price found for Altimmune Inc
No recent average analyst rating found for Altimmune Inc

Company Overview Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabo...Read More

https://altimmune.com

910 Clopper Road, Gaithersburg, MD, United States, 20878

59

December

USD

USA

Adjusted Closing Price for Altimmune Inc (ALT)

Loading...

Unadjusted Closing Price for Altimmune Inc (ALT)

Loading...

Share Trading Volume for Altimmune Inc Shares

Loading...

Compare Performance of Altimmune Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ALT

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Altimmune Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc 0.00 (0.00%) USD109.10B 27.47 20.00

ETFs Containing ALT

Symbol Name ALT's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Altimmune Inc (ALT) Stock

Based on ratings from 5 analysts Altimmune Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 8 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on ALT's stock to indicate if its a good dividend stock.

Based on targets from 5 analysts, the average taret price for ALT is USD 17.89 over the next 12 months. The maximum analyst target price is USD 25 while the minimum anlayst target price is USD 12.

ALT stock's Price/Earning ratio is 34.35. Our analysis grades ALT stock's Price / Earning ratio at F. This means that ALT stock's Price/Earning ratio is above 81% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ALT may be a overvalued for its sector.

The last closing price of ALT's stock was USD 8.01.

The most recent market capitalization for ALT is USD 0.57B.

Based on targets from 5 analysts, the average taret price for ALT is projected at USD 17.89 over the next 12 months. This means that ALT's stock price may go up by +123.33% over the next 12 months.

We can't find any ETFs which contains Altimmune Inc's stock.

As per our most recent records Altimmune Inc has 59 Employees.

Altimmune Inc's registered address is 910 Clopper Road, Gaithersburg, MD, United States, 20878. You can get more information about it from Altimmune Inc's website at https://altimmune.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...